Abstract:Background: For patients with heart failure (HF), the effect of angiotensin receptor-neprilysin inhibitors (ARNIs, sacubitril/valsartan) on cardiac remodeling has been found to be superior to angiotensin-converting enzyme inhibitors (ACEI). However, little data have described the impact of early-initiation ARNI in patients with acute anterior ST-segment elevation myocardial infarction (STEMI). Methods: In this prospective, randomized, double-blind, parallel-group trial, we enrolled 131 anterior STEMI patients who were treated with primary percutaneous coronary intervention (PCI) between February 2019 and December 2019. All patients received standard STEMI management and were divided into 2 groups (ARNI/enalapril). Primary efficacy outcomes were the between-group difference in change (from baseline to 4-, 12-, and 24-week) in N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration, left ventricular ejection fraction (LVEF), and left ventricular end-systolic volumes and end-diastolic volumes (LVESV and LVEDV). Secondary outcomes were determined by a composite of death, reinfarction, outpatient HF or HF hospitalization, malignant arrhythmia, and stroke. Safety outcomes included worsening renal function, hypotension, hyperkalemia, angioedema and cough. Results: We found that NT-proBNP concentration decreased more in the ARNI group than in the enalapril group [4 weeks: ratio of ARNI vs. enalapril 0.36, 95% confidence interval (CI): 0.24 to 0.52, P<0.001; 12 weeks: 0.54, 95% CI: 0.35 to 0.79, P<0.001; 24 weeks: 0.53, 95% CI: 0.32 to 0.83, P<0.001). When compared to the enalapril group, the ARNI group patients had a significant reduction in LVEDV (P<0.001) and LVESV (P<0.001), and an improvement in LVEF (P=0.011) at 24 weeks. Secondary outcomes occurred in 13 participants (20.3%) in the ARNI group and 22 participants (34.4%) in the enalapril group [hazard ratio (HR), 0.56; 95% CI: 0.28 to 1.12; P=0.102]. The incidence of outpatient HF or HF hospitalization in the ARNI group was significantly lower than that in the enalapril group (HR, 0.36; 95% CI: 0.14 to 0.94; P=0.037). There were no significant differences in the safety between the 2 groups. Conclusions: For patients with acute anterior STEMI undergoing primary PCI, early initiation of ARNI provided significant clinical benefits. Trial registration: Chinese Clinical Trial Registry (ChiCTR2100042944) registered on February 1, 2021.

Reevaluate the effect of ACEI/ARB therapy at discharge on patients with STEMI in the contemporary reperfusion era

Long-Term Prognosis of Different Reperfusion Strategies for ST-Segment Elevation Myocardial Infarction in Chinese County-Level Hospitals: Insight from China Acute Myocardial Infarction Registry

Role of ST‐Segment Resolution Alone and in Combination with TIMI Flow after Primary Percutaneous Coronary Intervention for ST‐Segment–Elevation Myocardial Infarction

Reperfusion strategies on the clinical outcomes of ST-elevation myocardial infarction patients over 80 years old in China

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

The role of late reperfusion in ST-segment elevation myocardial infarction: a real-world retrospective cohort study

Complete Revascularization Versus Culprit-Only Revascularization in ST-segment Elevation Myocardial Infarction and Multivessel Disease Patients Undergoing Primary Percutaneous Coronary Intervention: A Meta-Analysis and Trial Sequential Analysis

Abstract 10950: Real-World Practice of Reperfusion and Revascularization in Patients with St-Segment Elevation Myocardial Infarction in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project

Treatment delay and reperfusion management of acute ST-segment elevation myocardial infarction: analysis of the China STEMI Care Project Phase 1

E0258 Current Clinical Practice and Guideline Application in Therapies of ST Segment Elevation ACS Inpatient in a Multi-Provincial Study in China: Results of BRIG Project

Short- and Long-Term Outcomes in Patients With Right Ventricular Infarction According to Modalities of Reperfusion Strategies in China: Data From China Acute Myocardial Infarction Registry

Impact of Angina Prior to Acute ST-elevation Myocardial Infarction on Short-Term Outcomes after Primary Percutaneous Coronary Intervention: Results from the Shanghai Registry of Acute Coronary Syndrome (SRACE).

Influence of percutaneous coronary intervention timing on the prognosis of patients with acute ST segment elevation myocardial infarction

Comparison of long-term outcomes of complete vs. incomplete revascularization in elderly patients (≥75 years) with acute coronary syndrome and multi-vessel disease undergoing percutaneous coronary intervention

Thirty-day Outcomes of In-Hospital Multi-Vessel Versus Culprit-Only Revascularization Strategy for ST-segment Elevation Myocardial Infarction with Multivessel Coronary Disease.

Association of Β-Blocker Therapy at Discharge with Clinical Outcomes after Acute Coronary Syndrome in Patients Without Heart Failure

Comparing the efficacy of angiotensin receptor-neprilysin inhibitor and enalapril in acute anterior STEMI patients after primary percutaneous coronary intervention: a prospective randomized trial

Percutaneous coronary revascularization versus medical therapy in chronic coronary syndromes: An updated meta‐analysis of randomized controlled trials

AS-019: Impact of Revascularization Time on Outcomes of Patients with Acute ST-Elevation Myocardial Infarction Undergoing Emergent and Delayed Percutaneous Coronary Intervention

Assessing the Association of Appropriateness of Coronary Revascularization and 1-Year Clinical Outcomes for Patients with Stable Coronary Artery Disease in China

Long-term outcomes in inferior ST-segment elevation myocardial infarction patients with right ventricular myocardial infarction